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qualityAbstract Context:Medicated chewing gum (MCG) of Domperidone Maleate (DM) was developed
by direct compression method with the goal to achieve quick onset of action and to improve patient
compliance. Objective: Formulation development of MCG of DM and optimization of the formula-
tion by screening of different excipients.Material andmethods:MCGcontainingDMwas prepared by
screening different concentrations of sweeteners, ﬂavouring agents, softening agents, lubricants and
anti-adherents by changing one variable at a time. Performance evaluation was carried out by eval-
uating size, shape, thickness, taste, scanning electronmicroscopy, texture analysis, in vivo drug release
study, ex vivo buccal permeation study and by studying statistical analysis for quality.Results and dis-
cussion: The statistical analysis showed signiﬁcant improvement in organoleptic properties such as
chewable mass, product taste, product consistency, product softness, total ﬂavour lasting time and
pharmaceutical properties like micromeritic properties after incorporation of appropriate excipients
in an optimum amount in ﬁnal optimizedMCG formulation. In vivo drug release study showed 97%
DM release whereas ex vivo buccal permeation study through goat buccal mucosa exhibited 11.27%
DMpermeationwithin 15 min indicating its potential for increasing bioavailability by decreasing time
of onset. The optimized formulation showed good surface properties and the peak load required for
drug release was found to be acceptable for crumbling action.Conclusion:The developed formulation
of medicated chewing gum can be a better alternative to mouth dissolving and conventional tablet
formulation. It may be proved as a promising approach to improve the bioavailability as well as to
improve patient compliance.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nausea and vomiting are the most commonly occurring symp-
toms in majority of pathophysiological conditions such as
motion, cancer, pregnancy, and postoperative conditions.
Nausea refers to feeling of impending vomiting. Vomiting
154 M. Paradkar et al.refers to forceful expulsion of contents of the stomach and the
proximal small intestine (Pleuvry, 2006).
Antiemetic drugs are used to prevent or suppress vomiting.
They act by blocking several receptors located in vomiting cen-
tres such as H1 histaminic, dopamine D2, 5-HT3 receptor, mus-
carinic, and neurokinin1(NK1) receptor. Drugs such as
Anticholinergics, H1-antihistamines, Neuroleptics, 5-HT3
antagonists act by penetrating blood brain barrier which leads
to sedation. Prokinetic drugs such as metoclopramide and
domperidone maleate act as dopamine D2 blockers. Their
antiemetic activity is due to antagonism of D2 receptors in
Chemoreceptor Trigger Zone (CTZ) which is located outside
of the blood brain barrier so they do not cause side effects
related to brain and hence do not cause disturbance in regular
activities such as driving, and ofﬁce work. It is reported that
metoclopramide has more side effects as compared to
Domperidone maleate (Tripathi, 2003).
Domperidone Maleate (DM) has very low oral bioavail-
ability (15%) owing to its extensive metabolism in liver and
gut wall (Tripathi, 2003). It is available in the form of tablets,
capsules, suspensions, injections, sustained release capsules,
etc. But these formulations have several disadvantages such
as difﬁculty in swallowing tablets or capsules which also
requires water. Besides these, suspension does not possess
pleasant taste and dose accuracy. Patients suffering from try-
panophobia experience difﬁculty in medication by needle. In
addition, drug if given by oral route, undergoes ﬁrst pass meta-
bolism that decreases bioavailability of DM. Formulations of
DM investigated by various researchers are coevaporates
(Nagarsenker et al., 2000), fast dissolving tablet (Bhatt and
Trivedi, 2012), orodispersible tablet (Islam et al., 2011), etc.
Chewing gum is a pleasure that almost everyone enjoys.
Chewing gum usually consists of a gum core, which may or
may not be coated. Medicated chewing gums are deﬁned by
the European Pharmacopoeia and the guidelines for pharma-
ceutical dosage forms issued in 1991 by the Committee for
Medicinal Products for Human Use (CPMP) as ‘solid single
dose preparations with a base consisting mainly of gum that
are intended to be chewed but not to be swallowed, providing
a slow steady release of the medicine contained’ (European
Pharmacopoeia, 2010). Chewing gum has also being exploited
for the drug delivery and many times referred as mobile drug
delivery system (Ingole et al., 2012). Medicated chewing gum
(MCG) gives local (treatment of oral disease) as well as sys-
temic action (buccal absorption or by swallowing saliva).
MCG helps to increase patient compliance by fast onset of
action and by improved bioavailability of drug as some
amount of drug is absorbed through the buccal mucosa. It
can also be administered without water (Jacobsen et al.,
2004; Chaudhary and Shahiwala, 2010; Chaudhary and
Shahiwala, 2012). MCG has been exploited for various drugs
such as cetirizine (Stojanov and Larsen, 2012; Swamy et al.,
2012), dextromethorphan hydrobromide (Swamy et al.,
2012), dimenhydrinate hydrochloride (Mehta and Trivedi,
2011), nicotine (Morjaria et al., 2004; Cherukuri et al., 2000),
antacids (Zyck et al., 2003), miconazole (Pedersen and
Rassing, 1990), aspirin (Woodford and Lesko, 1981), caffeine
(Tyrpin et al., 2002), antimicrobial decapeptide (Dong et al.,
2005), ondansetron hydrochloride (Nagaich et al., 2010), and
nystatin (Andersen et al., 1990).
The aim of present research work was to formulate medi-
cated chewing gum of DM to fasten the onset of action andto improve the bioavailability so as to get the quick relief from
nausea and vomiting with greater patient compliance.
2. Methods
2.1. Materials
DM was received as gift sample from Vasudha Pharma
Chemical Limited (Hyderabad, India). Health In Gum
(HIG PWD 02) was received as gift sample from Cafosa
(Barcelona, Spain). All other ingredients and solvents used
were of analytical or pharmaceutical grade.
2.2. Drug excipients compatibility study
2.2.1. Fourier Transform Infrared Study (FTIR)
The drug-excipient compatibility study was carried out by
FTIR. FTIR spectra of the (a) pure drug, (b) gum base and
(c) mixture of drug:excipients (1:99) were recorded. The sam-
ples were prepared by weighing and homogenously dispersing
with dried KBr in a mortar and pestle, and compressing the
powder under vacuum with a compression force using round
ﬂat face punch for three minutes to produce a pellet compacts.
The sample was placed in the IR light path using a FTIR
Instrument (NICHOLET 6700, Thermo Scientiﬁc, USA).
Spectra were recorded in the wavelength region of 4000–
400 cm1. The peaks were observed for any types of interac-
tion between the drug and excipients (Dixit, 2013).
2.3. Formulation development of MCG
The technique of screening of one excipient at a time was
adopted. The whole process of the formulation development
is given in Fig. 1.
2.4. Pre-compression study
Flow properties of gum base and drug: excipient mixtures were
determined by measurement of angle of repose, bulk density,
tapped density, compressibility index (CI) and hausner’s ratio.
2.5. Preparation of medicated chewing gum
Medicated chewing gums were prepared by direct compression
method. In this method, the ﬂavour was added in accurately
weighed DM with continuous mixing in a mortar for 15 min.
Flavoured drug was screened through 30# sieve (0.600 mm)
followed by addition of accurately weighed and 30# pre-sifted
gum base, anti-adherent and sweeteners and blended for
10 min. 30# pre-sifted lubricant was precisely added and
blended for 10 min. Finally, the prepared blend of formulation
was compressed on a tablet compression machine (Rimek Mini
Press-II, Karnavati Engineering) (Rao et al., 2011).
2.6. Screening of excipients by human volunteers
MCGs were evaluated for several organoleptic properties such
as chewability, ﬂavour lasting time, sweetness, and softness in
a panel of healthy human volunteers (n= 6). The permission
for conducting these studies was obtained from Institutional
Step-1
Step-2 
Step-3 
Step-4 
Step-5 
Step-6 
Selection and optimization of Chewable Mass 
(Batch M1-M3) 
Selection and optimization of Flavor 
(Batch M4-M8) 
Selection and optimization of Sweetener 
(Batch M9-M28) 
Selection and optimization of Softener 
(Batch M29-M35) 
Selection and optimization of Lubricant 
(Batch M36-M41) 
Selection and optimization of Anti-adherent 
(Batch M42-M46) 
Chewable mass selected: 1000 mg 
Flavour selected: Cherry 10 mg 
Sweetener selected:  MAG 30 mg and 
Aspartame 50 mg (Combination) 
Softener selected:  Soyalecithin 20 mg 
Lubricant selected:  Acryflow 10 mg 
Anti-adherent selected:  Talc 50 mg 
Figure 1 Steps of selection and optimization of the excipients.
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IECHR/PG/2012-2013/R11.02].
Volunteers those who signed the informed consent form
(Annexure I) were selected. Before starting the experiment,
all volunteers were instructed to rinse their mouth thoroughly
and were asked about any adverse effect towards DM. They
reported the responses of the tests in questionnaire form
(Annexure II). Selection and optimization of an individual
excipient was performed by screening each excipient with
respect to desired criteria. The prepared formulation com-
position is shown in Table 1.
2.7. Optimization of chewable mass
To obtain good chewability of dosage form, the MCGs were
formulated in different sizes (Batch M1–M3) and evaluated
by healthy human volunteers. They were allowed to chew
MCG of different sizes and MCG with good chewability was
selected based on scale of chewability as mentioned in
Table 2. The optimized mass was kept constant for further
studies.
2.8. Screening of ﬂavours
To formulate MCGs with good ﬂavour lasting time, different
ﬂavours such as chocolate, cherry, peppermint oil, water-
melon, orange were screened. MCGs containing different ﬂa-
vours were prepared (Batch M4–M8). MCGs were allowed
to chew by healthy human volunteers up to 5 min and they
were asked to report the ﬂavour lasting time. MCG which
had longer ﬂavour lasting time was selected for further studies.2.9. Screening of sweeteners
Sweeteners are the important part of the MCGs. Drug has
moderate bitter taste and so it needs to be masked to enhance
patient compliance. To mask the bitter taste of DM, different
sweeteners such as mannitol, acesulfame, aspartame, gly-
cyrrhiza, mono-ammonium glycyrrhizinate (MAG) (Batch
M9–M28) were screened. Accurately weighed sweeteners were
taken and MCGs were prepared by direct compression
method. Taste acceptability was measured by a panel of volun-
teers (n= 6). Each volunteer was asked to hold MCG for 5–
10 s, then spat out and to report taste rank as shown in
Table 2. Formulation with excellent taste masking (taste rank:
4) was selected for further studies (Dixit, 2013).
2.10. Screening of softening agents
To obtain good softness in MCG, screening of different soften-
ing agents such as glycerol, stearic acid, soya lecithin was per-
formed. Accurately weighed softener was taken (Batch M29–
M35) and MCGs were evaluated by six healthy human volun-
teers based on the scale of softness as shown in Table 2.
2.11. Screening of lubricants
Different lubricants such as Magnesium Stearate and
Acryﬂow were selected by taking different concentrations
and by measuring ﬂow characteristics of the drug: excipient
mixture. MCGs containing different concentrations of lubri-
cant (Batch M36–M41) were observed for smooth ejection
during compression in tablet punching machine. MCG with
Table 1 Selection and optimization of DM Medicated chewing gum formulation (M1–M46).
Category Ingredients Batch code
M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12 M13
Drug DM 10 10 10 10 10 10 10 10 10 10 10 10 10
Gum base Health in gum 480 580 980 980 980 980 980 980 880 973 880 920 880
Flavour Cherry – – – 10 – – – – 10 10 10 10 10
Orange – – – – 10 – – – – – – – –
Peppermint oil – – – – – 10 – – – – – – –
Water melon – – – – – – 10 – – – – – –
Chocolate – – – – – – – 10 – – – – –
Sweetener Mannitol – – – – – – – – 100 – – – –
Acesulfame – – – – – – – – – 7 – – –
MAG – – – – – – – – – – 100 – –
Aspartame – – – – – – – – – – – 60 –
Glycyrrhiza glabra – – – – – – – – – – – – 100
Total weight 500 mg 600 mg 1000 mg
Category Ingredients M14 M15 M16 M17 M18 M19 M20 M21 M22 M23 M24 M25 M26 M27 M28
Drug DM 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
Gum base Health in gum 963 953 943 933 923 913 820 820 830 840 850 870 890 900 910
Flavour Cherry 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
Sweetener Mannitol – – – – – – – –
Acesulfame 7 7 7 7 7 7 7 –
MAG – – – – – – 100 100 100 100 80 60 40 30 20
Aspartame 10 20 30 40 50 60 – 60 50 40 50 50 50 50 50
Glycyrrhiza glabra – – – – – – – – – – – – – –
Total weight 1000 mg
Category Ingredients M29 M30 M31 M32 M33 M34 M35 M36 M37 M38 M39 M40 M41 M42 M43 M44 M45 M46
Drug DM 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
Gum base Health in
gum
800 850 850 860 870 880 890 875 870 865 860 855 850 860 850 840 830 820
Flavour Cherry 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
Sweetener MAG 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30
Aspartame 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50
Softener Glycerol 100 – – – – – – – – – – – – – – – –
Stearic acid – 50 – – – – – – – – – – – – – – – –
Soyalecithin – – 50 40 30 20 10 20 20 20 20 20 20 20 20 20 20 20
Lubricant Acryﬂow – – – – – – – 5 10 15 20 25 30 10 10 10 10 10
Anti-
adherent
Talc – – – – – – – – – – – – – 10 20 30 40 50
Total weight 1000 mg
Table 2 Score of different test parameters.
Scale 0 1 2 3 4
Chewability Very poor Poor Passable Good Very good
Bitterness Bitter Moderate to bitter Slightly bitter Tasteless/taste masked Excellent taste masking
Softness Very hard Hard Passable Soft Very soft
156 M. Paradkar et al.less concentration of lubricant and smooth ejection was
selected for further studies.
2.12. Screening of anti-adherents
Different concentrations of anti-adherent (talc) were screened.
MCGs containing different concentrations of anti-adherent
(Batch M42–M46) were observed for smooth ejection andstickiness to die or punch of tablet punching machine.
MCGs with less concentration of anti-adherent and less/no
stickiness were selected for formulation of MCG.
2.13. Post-compression studies
Appearance, size, shape, thickness and diameter of MCG were
observed by taking ten medicated chewing gum randomly.
Table 3 Flow properties of gum base and Drug:Excipients
(D:E) mixture.
Flow properties Serial no Average valuesa
Bulk density (gm/mL) Gum base 0.66 ± 0.06
D:E mixture 0.67 ± 0.025
Tapped density (gm/mL) Gum base 0.73 ± 0.07
D:E mixture 0.65 ± 0.051
Hausner’s ratio Gum base 1.09 ± 0.011
D:E mixture 1.10 ± 0.02
Compressibility index (%) Gum base 9.2 ± 0.72
D:E mixture 9.46 ± 0.17
Angle of repose (h) Gum base 30.70 ± 1.02
D:E mixture 29.49 ± 2.41
Evaluation of medicated chewing gum of anti-emetic drug 157Thickness and diameter were measured by digital vernier cali-
per and appearance, size, shapes of the medicated chewing
gums were evaluated visually. The hardness of six medicated
chewing gums was determined by diametrical compression
using a Monsanto hardness tester and the average value was
calculated and expressed as kg/cm2. Weight variation test
was performed by selection of twenty medicated chewing
gum randomly. They were weighed individually and the aver-
age weight was calculated from total weight. Then percentage
deviation from the average was calculated (European
Pharmacopoeia, 2010).
Percentage weight variation¼ðWeight of individualMCG=
Average weight of 20MCGsÞ 100Table 4 Results of post-compression study of optimized
MCG (M46).
Parameters Average values
Weight variationa 1.004 ± 0.004
Diameterb (cm2) 12.48 ± 0.030
Thicknessb (mm) 6.671 ± 0.009
Hardnessc (kg/cm2) 2.666 ± 0.577
Friabilityb (%) 0.196 ± 0.099
Content uniformityb (%) 98.25 ± 8.404
Loss on dryingc (%) 0.40 ± 0.005
a Data are shown as average of n= 20 ± SD.
b Data are shown as average of n= 10 ± SD.
c Data are shown as average of n= 6± SD.
a Data are shown as average of n= 3± SD.2.14. Friability
Ten MCGs were randomly taken and carefully de-dusted prior
to weighing. They were weighed and placed in the Roche
Friabilator (EF-2, Electrolab) which was rotated for 100 rev-
olutions at 25 rpm. The medicated chewing gums were then de-
dusted and reweighed. A maximum loss of mass (obtained
from a single test or from the mean of three tests) was calcu-
lated in percentage (Chaudhary and Shahiwala, 2010).
2.15. Content uniformity test
The individual contents of active substance of 10 dosage units
which were taken randomly were determined. The 10 dosage
forms were crushed in mortar and powder equivalent to
10 mg of DM was taken. The powder was dissolved in
100 ml of conical ﬂask containing phosphate buffer pH 6.8.
The absorbance measurements of these solutions were taken
by UV–Visible spectrophotometer at 284 nm. The formulation
complies with the test if the individual content is between 85%
and 115% of the average content (European Pharmacopoeia,
2010).Figure 2 FTIR spectra of (a) pure drug, (b) p2.16. % Loss on drying
%Loss on drying was measured in IR moisture balance instru-
ment (MA 45 model, Sartorius, India) for 4 min. Theure gum base and (c) drug:excipients (1:99).
158 M. Paradkar et al.optimized MCG (M46 batch) was placed in aluminium disc in
moisture balance. The temperature was set at 105 C and the
% loss on drying (% LOD) was determined (Vegada et al.,
2012).
2.17. Evaluation of optimized batch
2.17.1. Statistical analysis of MCG quality
For product quality assessment, a sensory panel of 6 human
volunteers had been formed. They had given two formulations
for chewing (a) M46 (ﬁnal optimized MCG) (b) M4 (MCG
containing only gum base with DM and ﬂavour) to evaluate
organoleptic properties such as Taste, Consistency, Softness,
Flavour lasting time. Volunteers had given score individually
by chewing both the products. After assessment, ﬁlled forms
with score (x out of 4) were received from volunteers. The
average score was calculated for each of the four different
qualities. Paired t-test was applied to test whether there is
any signiﬁcant improvement in product quality after excipient
treatment or not (Chaudhary and Shahiwala, 2010).
2.17.2. Scanning electron microscopy (SEM)
Morphological surface characteristic of prepared MCG was
analysed using scanning electron microscope. The medicated
chewing gums of M46 (optimized batch) and M34 (MCG with-
out lubricant) were ﬁxed on aluminium stubs with double sided
tape and examined in Jeol scanning electron microscope 5610
LV using an accelerating voltage of 2.0–30 kV, at magniﬁca-
tion of 250·, 500· and 1000· (Bratbak, 1993).
2.17.3. Texture analysis by instrument
Instrumental texture analysis is mainly concerned with the
evaluation of mechanical characteristics where a material is
subjected to a controlled force from which a deformation curve
of its response is generated. Texture property of directly com-
pressed MCG was evaluated using Brookﬁeld QTS-25 tex-
ture analyser. It was recommended to use a compression
probe with surface area of 4 mm2. During evaluation, a con-
stant force was applied on the surface of self-supporting
MCG and upon fracture it was withdrawn. Deformation curve
was recorded and interpreted. Peak load required for deforma-
tion of MCG was determined (Chaudhary and Shahiwala,
2010).
2.17.4. In-vivo drug release study
The in vivo drug release of DM fromMCG during mastication
was studied by recruiting a panel of six numbers of volunteers
and scheduled chew-out studies for determination of % drug
release fromMCG. Each person was allowed to chew one sam-
ple of the DM MCG for a particular time period, i.e. 0.5, 1, 2,
5, 10, and 15 min. After chewing, chewed out gum samples
were collected from volunteers, stretched out up to maximum
and cut into small pieces and dispersed in a 100 ml volumetric
ﬂask containing phosphate buffer pH 6.8, which was then soni-
cated for 10 min with heating. The sonicated sample was ﬁl-
tered and analysed by a UV spectrophotometer at 284 nm to
determine the residual drug content present in MCG. The
‘‘amount of drug released during mastication’’ was calculated
by subtracting the ‘‘amount of the residual active ingredient’’presents in the gum after chewing from ‘‘the total content’’
(Chaudhary and Shahiwala, 2010; Noehr-Jensen et al., 2006).
Amount of drug released during mastication ¼ Total content
Amount of the drug in residual active ingredient:2.17.5. Ex-vivo buccal permeation study
Buccal mucosa was obtained from the approved slaughter
house. The permission for conducting this study was obtained
from Institutional Animal Ethics Committee (IAEC).
[Protocol No: RPCP/IAEC/2012-2013/MPH-PT-26]. Goat
buccal mucosa was cleaned and placed between a donor com-
partment and a receiver compartment of the Franz diffusion
cell. To simulate oral conditions, phosphate buffer of salivary
pH (pH 6.8) was ﬁlled in the donor compartment and phos-
phate buffer of blood pH (pH 7.4) was ﬁlled in the receiver
compartment. The average amount of DM, which was released
from optimized formulation after 15 min of chewing, was
placed in the donor compartment. It was allowed to permeate
through buccal mucosa for 30 min. At 5 min interval the sam-
ple was collected from the receiver compartment and analysed
by the UV-spectrophotometer at 284 nm, to determine the
total content of DM permeated through buccal mucosa. The
study was performed in triplicate (Chaudhary and
Shahiwala, 2010).
3. Result and discussion
3.1. Drug excipients compatibility study
The FTIR spectra as shown in Fig. 2 indicated that there were
no changes in standard wave number of the drug and excipi-
ents. So, there is no interaction between pure drug, pure
gum base and excipients. It indicates that drug and excipients
are compatible.
3.2. Pre-compression studies
The results of pre-compression studies are shown in Table 3.
Angle of repose of gum base and drug: excipients mixture
was found to be 30.70 ± 1.02 and 29.49 ± 2.41, respectively.
Angle of repose less than or equal to 30 indicates excellent
ﬂow property so it was concluded that the gum base and
drug:excipients mixture had excellent ﬂow property.
Compressibility index for gum base and drug: excipients mix-
ture was found to be 9.20 ± 0.72% and 9.46 ± 0.17%,
respectively, which indicates excellent compressibility of
gum base and mixture. Compressibility is the parameter used
to determine compression efﬁciency of powder during com-
pression. Compressibility index less than 10% indicates excel-
lent compressibility. Hausner’s ratio for gum base and
mixture was found to be 1.09 ± 0.011 and 1.10 ± 0.02,
respectively, which represents good ﬂowability because
Hausner’s ratio between 1.00 and 1.11 represents excellent
ﬂowability. Thus, from the results it was indicated that the
gum base and mixture of drug and excipients showed excel-
lent ﬂow property and compressibility which is favourable
for direct compression.
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Figure 3 Comparison of scores obtained by two different MCG products: (A) Taste, (B) Consistency, (C) Softness and (D) Flavour
Lasting Time.
Table 5 Average score for four different qualities of optimized MCG (M46).
Parameter Taste Consistency Softness Flavour lasting time
Batchesa a b a b a b a b
Average scoreb 3.66 ± 0.516 0.833 ± 0.752 3.16 ± 0.751 1.83 ± 0.75 3.33 ± 0.816 0.83 ± 0.752 3.5 ± 0.547 1.83 ± 1.47
a Where ‘‘a’’ is batch M45 and ‘‘b’’ is batch M4.
b Data are shown as average of n= 6± SD.
Table 6 Applied paired t-test for optimized MCG (M46)
quality evaluation.
MCG quality tcal ttab
Taste 9.219 2.015
Consistency 3.162 2.015
Softness 7.319 2.015
Flavour lasting time 2.5 2.015
Evaluation of medicated chewing gum of anti-emetic drug 1593.3. Formulation and development of medicated chewing gum
The details of all the batches are given in Table 1.
3.4. Optimization of chewable mass
The batches from M1 to M3 were formulated to optimize
chewable mass from the response of healthy human volunteers
(n= 6) and it was found that MCG of Batches M1 (500 mg)
and M2 (600 mg) showed poor chewability due to less chew-
able mass which was not favourable for MCG. The batch
M3 (1000 mg) showed very good chewability due to proper
chewable mass. So, the size of medicated chewing gum was
ﬁxed as 1000 mg for further formulation.
3.5. Screening of ﬂavours
The batches of MCGs containing different ﬂavours were for-
mulated (M4–M8). The responses were observed in healthy
human volunteers (n= 6) and it was observed that the ﬂavour
lasting time for M5 (orange) and M7 (water melon) was about
1 min so imparted bitter taste during mastication. M6 (pepper-
mint oil) had ﬂavour lasting time up to 2 min. The M8 (choco-
late) has good ﬂavour lasting time up to 4 min but that was
lower as compared to cherry ﬂavour. The highest ﬂavour last-
ing time observed with M4 (cherry) was up to 5 min. So, M4
batch containing cherry as ﬂavour was selected.
3.6. Screening of sweeteners
Sweeteners are the important part of the MCGs. Drug has
moderate bitter taste and so, it needs to be reduced or to be
masked to enhance patient compliance. The batchesM9–M28 were formulated using different concentration of
sweeteners. The responses were observed in healthy human
volunteers (n= 6). Based on the response it was concluded
that batch M4 (without sweetener) has bitter taste which is
rated 0 as per the taste rank shown in Table 2. In the batches
M9–M13 containing different sweeteners, it was observed that
these batches had moderate bitterness. So, it was decided to
formulate MCG with the blend of sweeteners so as to get the
complete taste masking.
In the MCGs containing different Blend of Sweeteners, it
was found that the batch M21 containing highest amount of
MAG: Aspartame (100 mg: 60 mg), masked the bitter taste
but it had some bitter after taste that may be due to aspartame
or MAG. To optimize the concentration of MAG and aspar-
tame, further batches (M22–M28) were formulated. Batch
M22 containing 50 mg of aspartame showed complete taste
masking so it was optimized for further formulation. To test
the effectiveness of MAG on taste masking the amount of
MAG was decreased further. Monoammonium glycyrrhizinate
(MAG) can be used as sweetness potentiator. The MCGs of
M27 (30 mg of MAG) showed proper taste masking. It was
concluded that batch M27 at amount (30 mg MAG: 50 mg
Aspartame) had excellent taste masking, so, this ratio was
selected for further formulation.
(A)
(B)
250x 500x 1000x
1000x500x250x
Figure 4 Scanning electron microscope images of medicated chewing gum: (A) M45. (B) M36 at 250· 500·, 1000· magniﬁcation.
160 M. Paradkar et al.3.7. Screening of softening agents
It was observed that batch M29 containing glycerol had good
softening property but it affects the ﬂow properties because of
viscous nature. The batch M30 containing stearic acid was
very hard to chew and had grittiness during mastication while
the batch M31 containing soya lecithin provided very good
softness and consistency to the MCG, so, it was selected as
softening agent for further study.
Soya lecithin also helps to suppress bitter taste of DM
(Sharma and Lewis, 2010). Further, it was found that the con-
centration of softener may affect the release of drug from
MCG. So, concentration of softener was optimized based on
drug release. The batches M31–M35 containing different con-
centration of soya lecithin (1–3% w/w) was formulated and
drug release study was performed in healthy human volun-
teers. It was found that M34 (2% soya lecithin) showed highest
drug release. The MCGs containing soya lecithin more than
2% were split into pieces during chewing which showed poor
acceptability. So, 2% soya lecithin concentration was opti-
mized and kept constant for further formulation.
3.8. Screening of lubricants
The batches (M36–M41) containing different concentrations
(0.5–3% w/w) of lubricant (Acryﬂow) were prepared.Magnesium stearate is most widely used as lubricant but
it was found that it retards dissolution of some APIs and
the magnesium salt sometimes shows incompatibility with
APIs (Allen and Luner, 2009). Acryﬂow is poly-hydroxy
stearate derivatives and it has nonreactive functional group,
so, it does not have incompatibility with APIs (Corel
Pharma Chem, 2013). The selection of lubricant was per-
formed based on its ﬂow properties and the results showed
that the angle of repose ranges from 31 to 36 which indi-
cates good ﬂowability. Hausner’s ratio was found in the
range 1.071–1.081 which indicates excellent ﬂowability.
The compressibility index was found to be 6.66 which indi-
cates excellent compressibility. Acryﬂow in the concentra-
tion of 1% w/w i.e. 10 mg (Batch M37) was selected as
lubricant as it showed good ﬂow properties, excellent com-
pressibility and smooth ejection from tablet punching
machine.
3.9. Screening of anti-adherent
The batches M42–M46 containing different concentration of
talc were prepared. The amount of talc selected based on
stickiness of MCGs to punch. It was found that in batch
M46, MCG did not stick to punch and was easy to eject out.
So, batch M46 containing 50 mg talc was selected for ﬁnal
formulation.
Table 7 Peak load of optimized batch (M46) by texture
analysis.
Serial
no.
Probe
(mm)
Compression
cycle
Peak load
(gm)
Averagea (gm)
1 4 1 12,248 11,062 ± 1225.6
2 4 1 9847
3 4 1 11,043
a Data are shown as average of n= 3± SD.
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Figure 6 In-vivo drug release in healthy human volunteers (A–
F).
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The results of the post-compression studies are shown in
Table 4. From the visual inspection by healthy volunteers, it
was found that the appearance, size, shape of optimized
MCG were aesthetic. The mean thickness (n= 10) and mean
diameter (n= 10) were uniform with value ranging between
6.662–6.681 mm and 12.46–12.52 mm2, respectively. The aver-
age weight of compresses MCG formulations was within the
range of 0.998–1.008 mg. So, all compressed MCGs passed
weight variation test for compressed tablets as per European
Pharmacopoeia. The weight of all the MCGs was found to
be uniform with low standard deviation values. The measured
hardness of tablets ranged between 2 and 3 kg/cm2 which
ensures good handling characteristics of MCG. The % friabil-
ity was less than 1% in all the formulations ensuring that the
MCGs were mechanically stable. The percentage drug content
of the all the MCGs ranged within 98.25% to 105.67%, which
was within acceptable limits indicating dose uniformity in each
MCG. The mean % of loss on drying of optimized MCGs was
found to be in range of 0.40–0.41%, which is within acceptable
limits indicating higher stability of MCGs.
3.11. Evaluation of optimized batch
3.11.1. Statistical Analysis of MCG quality
The statistical analysis of MCG (a) M46 (b) M4 was per-
formed for its quality evaluation. The Organoleptic properties
such as taste, consistency, softness, ﬂavour lasting time were
evaluated from the response of healthy human volunteersFigure 5 Peak load curve of optimized batc(n= 6). The Comparison of score obtained from responses
was represented in Fig. 3. The average score was calculated
for each of four different qualities and the results of which
are as shown in Table 5.
Paired t-test was applied to test any signiﬁcant improve-
ment in product quality after excipients treatment and the
results for which are as shown in Table 6. It was concluded
that for all quality parameters, tcal > ttab so there is a signiﬁ-
cant improvement in product quality after treatment with
excipients. It was conﬁrmed that there is a signiﬁcant improve-
ment in the product taste, product consistency, product soft-
ness and total ﬂavour lasting time after incorporation of
appropriate excipients in an optimum amount in M45 (ﬁnal
optimized MCG formulation).
3.11.2. Scanning Electron Microscopy (SEM)
The SEM images (Fig. 4) clearly indicate that optimized
formulation has smoother surface as compared to MCG with-
out lubricants. So, it was concluded that M45 can increase
patient acceptance due to aesthetic surface property.
3.11.3. Texture analysis study
It was found that peak load required for deformation of medi-
cated chewing gum was 11062 ± 1225.6 g with 4 mm probe.h (M46) obtained from texture analyzer.
Table 8 In-vivo drug release in six healthy volunteers.
Serial no. Time (minutes) % Drug releasea
Volunteer A Volunteer B Volunteer C Volunteer D Volunteer E Volunteer F
1 0 0 0 0 0 0 0
2 0.5 65.76 ± 0.885 65.72 ± 3.500 68.90 ± 3.059 65.73 ± 0.689 64.67 ± 1.271 65.01 ± 2.259
3 1 75.48 ± 0.413 71.71 ± 2.63 76.56 ± 2.121 72.71 ± 1.574 72.71 ± 1.574 72.59 ± 2.1452
4 2 81.81 ± 2.390 83.25 ± 2.95 82.45 ± 2.492 80.35 ± 0.560 79.63 ± 2.283 77.86 ± 2.888
5 5 94.37 ± 1.414 94.80 ± 1.013 93.10 ± 3.103 88.44 ± 2.318 87.11 ± 2.938 86.84 ± 1.550
6 10 96.03 ± 0.915 96.20 ± 0.679 95.23 ± 1.389 93.09 ± 0.536 92.55 ± 2.117 90.09 ± 1.254
7 15 97.14 ± 0.122 97.42 ± 0.805 96.84 ± 0.921 97.72 ± 1.011 96.95 ± 1.211 96.82 ± 1.345
a Data are shown as average of n= 6± SD.
0 
20
40
60
80
100
120
0.5 1 2 5 10 15
%
C
um
ul
at
iv
e 
 D
ru
g 
R
el
ea
se
Time (min)
A
B
C
D
E
F
Figure 7 In-vivo drug releases of six healthy human volunteers and comparison at speciﬁc time.
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Figure 8 Radar plot of drug release in healthy human volunteers
at speciﬁc time.
162 M. Paradkar et al.The MCG initially crumbles and then comes together to form
a chewable gum mass. The crumbling of the MCG allows DM
to be released and provides a faster release as compared to
conventional gums, which remain intact during the process(Jo´ja´rt et al., 2013). The results of texture analysis study are
given in Table 7 and Fig. 5.
3.11.4. In-vivo drug release study
The results of in vivo drug release at different time intervals are
as shown in Fig. 6. Individual % DM release is mentioned in
Table 8 and Fig. 7. From the results, it was observed that drug
release after 15 min of chewing was 97.15%. Initially, due to
the breaking of the MCG, the release of the drug was very fast
as it was observed that almost 80% of the drug was released
within 2 min. This is a good indication as the fast release of
drug resulted in the fast absorption and ultimately the fast
onset of action. The radar plot (Fig. 8) showed the % drug
release from MCG at speciﬁc time (0.5, 1, 2, 5, 10 and
15 min) in healthy human volunteers (A–F).
3.11.5. Ex-vivo buccal permeation study
The results of buccal permeation study of DM performed on
goat buccal mucosa are given in Fig. 9. From the results, it
was observed that the amount of drug permeated through buc-
cal mucosa was 1.09 mg (11.27%) in 15 min. It is hypothesized
from the results of the buccal permeation that the signiﬁcant
amount of the drug may permeated (absorbed) through the
buccal route, which may increase bioavailability of DM and
decrease onset time.
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Figure 9 Ex-vivo buccal permeation data.
Evaluation of medicated chewing gum of anti-emetic drug 1634. Conclusion
The study concludes the possibility of the formulation of the
directly compressible MCG of DM using HealthinGum
(gum base) with the improved taste by using combination of
the sweeteners. The ﬁrst pass metabolism associated with
DM can also be solved by the MCG, as the main site of
absorption is buccal. The MCG formulation of DM is a novel
approach for the treatment of nausea and vomiting associated
with motion sickness and other pathophysiological conditions.
MCG can increase patient compliance and patient acceptance
as well as increase the bioavailability of DM as it showed sig-
niﬁcant permeation through buccal mucosa. However, clinical
pharmacokinetic data are needed to prove it further.
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